Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor

Journal of Clinical Oncology · Published 2026-07-01 · DOI 10.1200/jco-26-00550

Free full text

Authors (16)

Toby A. Eyre, Yuqin Song, Olivier Hermine, Yuerong Shuang, Wojciech Jurczak, João Samuel Farias, Carolina Mahuad, Muhit Özcan, Ron D. Jachimowicz, Tianlei Chen, Elena Ivanova, Xiaotong Li, Gabriel Man, Priscille Bourquelot, Remus Vezan, Michael Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Eyre, T., Song, Y., Hermine, O., et al. (2026). Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00550

Related articles